MX2017008662A - Anticuerpos monoclonales anti-pd-1 y metodo para obtener los mismos. - Google Patents

Anticuerpos monoclonales anti-pd-1 y metodo para obtener los mismos.

Info

Publication number
MX2017008662A
MX2017008662A MX2017008662A MX2017008662A MX2017008662A MX 2017008662 A MX2017008662 A MX 2017008662A MX 2017008662 A MX2017008662 A MX 2017008662A MX 2017008662 A MX2017008662 A MX 2017008662A MX 2017008662 A MX2017008662 A MX 2017008662A
Authority
MX
Mexico
Prior art keywords
antibody
method therefor
monoclonal antibody
obtaining method
chain cdr1
Prior art date
Application number
MX2017008662A
Other languages
English (en)
Inventor
Zhou Haiping
Li Xiaomin
Zhou Junjie
PEI Shuang
Zan Yanlu
Bai Yi
Bai Xianhong
Original Assignee
Beijing dongfang biotech co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing dongfang biotech co ltd filed Critical Beijing dongfang biotech co ltd
Publication of MX2017008662A publication Critical patent/MX2017008662A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere al campo técnico de ingeniería de anticuerpos. Se proporcionan un anticuerpo monoclonal anti-PD-1 humano completo, un método de preparación del mismo, y usos de los mismos. Los anticuerpos monoclonales Anti-PD-1 se obtienen de una colección de anticuerpos completamente sintética por medio de separación por exclusión, y luego las colecciones de construcción de mutación de región CDR1-3 de cadena ligera y CDR1-3 de cadena pesada del anticuerpo obtenido se separan por exclusión en secuencia por medio de una tecnología de maduración por afinidad para obtener un anticuerpo anti-PD-1 de alta afinidad. El anticuerpo se puede usar para tratar tumores, inflamaciones, y enfermedades autoinmunes.
MX2017008662A 2015-06-09 2015-10-13 Anticuerpos monoclonales anti-pd-1 y metodo para obtener los mismos. MX2017008662A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510312910.8A CN105061597B (zh) 2015-06-09 2015-06-09 一种抗pd-1的单克隆抗体及其获得方法
PCT/CN2015/091842 WO2016197497A1 (zh) 2015-06-09 2015-10-13 一种抗pd-1的单克隆抗体及其获得方法

Publications (1)

Publication Number Publication Date
MX2017008662A true MX2017008662A (es) 2017-12-07

Family

ID=54491146

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008662A MX2017008662A (es) 2015-06-09 2015-10-13 Anticuerpos monoclonales anti-pd-1 y metodo para obtener los mismos.

Country Status (16)

Country Link
US (1) US20170240644A1 (es)
EP (2) EP3770177A1 (es)
JP (1) JP6588534B2 (es)
KR (1) KR101876689B1 (es)
CN (1) CN105061597B (es)
AR (1) AR105619A1 (es)
AU (1) AU2015398193B2 (es)
BR (1) BR112017010744A2 (es)
CA (1) CA2972833C (es)
EA (1) EA036779B1 (es)
HK (1) HK1215870A1 (es)
MX (1) MX2017008662A (es)
NZ (1) NZ728874A (es)
SG (1) SG11201705252UA (es)
TW (1) TWI659969B (es)
WO (1) WO2016197497A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105061597B (zh) * 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
EP3344656A1 (en) 2015-09-01 2018-07-11 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
AR106184A1 (es) 2015-09-29 2017-12-20 Celgene Corp Proteínas de unión a pd-1 y sus métodos de uso
AU2016348391A1 (en) 2015-11-03 2018-05-17 Janssen Biotech, Inc. Antibodies specifically binding TIM-3 and their uses
CN105566496B (zh) * 2015-11-26 2019-04-02 大庆东竺明生物技术有限公司 阻断人程序性死亡因子1(pd-1)功能的单克隆抗体及其编码基因和应用
CN107286242B (zh) * 2016-04-01 2019-03-22 中山康方生物医药有限公司 抗pd-1的单克隆抗体
CN107523548A (zh) * 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的t细胞及其用途
CN109475603B (zh) 2016-06-20 2023-06-13 科马布有限公司 抗pd-l1抗体
CN106046162B (zh) * 2016-06-21 2019-04-02 大庆东竺明生物技术有限公司 抗人程序性死亡因子1（pd-1）单克隆抗体的制备及应用
CN107814845B (zh) * 2016-09-14 2021-02-09 浙江特瑞思药业股份有限公司 新的抗pd-1纳米抗体及其应用
WO2018050027A1 (zh) * 2016-09-14 2018-03-22 北京韩美药品有限公司 一种能够特异性地结合pd-1的抗体及其功能片段
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
EP3515944A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING IMMUNE DISORDERS WITH PD-1 BINDING PROTEINS
CN107840887B (zh) * 2016-09-21 2022-03-25 基石药业（苏州）有限公司 一种新的pd-1单克隆抗体
CA3046082A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
CN110121510A (zh) * 2017-01-06 2019-08-13 克雷森多生物制剂有限公司 程序性细胞死亡(pd-1)的单结构域抗体
EP3571231A4 (en) * 2017-01-20 2020-12-02 Tayu Huaxia Biotech Medical Group Co., Ltd. ANTI-PD-1 ANTIBODIES AND USES THEREOF
CN108341871A (zh) * 2017-01-24 2018-07-31 三生国健药业（上海）股份有限公司 抗pd-1单克隆抗体及其制备方法和应用
CN106928348B (zh) * 2017-03-06 2020-08-21 哈尔滨医科大学 一种调控人体固有免疫的全人源单克隆抗体及其制备方法和应用
CN106939049B (zh) * 2017-04-20 2019-10-01 苏州思坦维生物技术股份有限公司 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
JP7257967B2 (ja) * 2017-05-01 2023-04-14 ザ チルドレンズ メディカル センター コーポレーション 抗ｐｄ１抗体試薬に関する方法および組成物
CN107082813A (zh) * 2017-05-17 2017-08-22 董克海 靶向pd‑1的嵌合抗原受体分子及其应用
JP2020532991A (ja) 2017-09-07 2020-11-19 オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド プログラム細胞死タンパク質１に対する抗体
CN107446048B (zh) * 2017-09-13 2021-03-30 北京韩美药品有限公司 一种能够特异性地结合pd-1的抗体及其功能片段
WO2019096136A1 (zh) * 2017-11-14 2019-05-23 拜西欧斯（北京）生物技术有限公司 抗pd-1抗体及其制备方法和应用
CN108218989B (zh) * 2017-11-29 2020-08-18 广西医科大学 抗PD-1的纳米抗体PD-1/Nb18及其制备方法与应用
CN108218988B (zh) * 2017-11-29 2019-10-11 广西医科大学 抗PD-1的纳米抗体PD-1/Nb52及其制备方法与应用
CN112513350A (zh) * 2017-12-18 2021-03-16 查尔斯河实验室公司 根本上多样的人类抗体文库
CN108250296B (zh) * 2018-01-17 2020-07-07 长春金赛药业有限责任公司 全人源抗人pd-l1单克隆抗体及其应用
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
US20210061912A1 (en) * 2018-03-20 2021-03-04 WuXi Biologics Ireland Limited Novel anti-pd-1 antibodies
KR102216576B1 (ko) * 2018-06-29 2021-02-17 국민대학교 산학협력단 Pd-1과 결합력이 증가된 pd-l1 변이체
CN111253486B (zh) * 2018-09-27 2023-09-29 再鼎医药(上海)有限公司 抗pd-1抗体及其用途
JP7126624B2 (ja) * 2018-10-10 2022-08-26 深▲せん▼華大生命科学研究院 抗ＢＣＭＡ一本鎖抗体ｓｃＦｖ、並びにその作製方法及びその使用
JP2022522668A (ja) * 2019-02-26 2022-04-20 ツイスト バイオサイエンス コーポレーション 抗体を最適化するための変異体核酸ライブラリ
CN110095612B (zh) * 2019-04-12 2022-05-10 河北仁博科技有限公司 一种基于spr快速筛选单克隆抗体的方法
CN110194798A (zh) * 2019-05-31 2019-09-03 杭州科兴生物科技有限公司 抗pd-l1单克隆抗体、片段及其医药用途
CN117447596A (zh) * 2019-06-30 2024-01-26 福州创方医药科技有限公司 一种靶向pd-1的单克隆抗体及其应用
CN112225809B (zh) * 2019-06-30 2023-09-05 福州创方医药科技有限公司 一种靶向pd-1的单克隆抗体及其应用
TWI809286B (zh) 2019-07-05 2023-07-21 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
TW202120550A (zh) 2019-08-08 2021-06-01 日商小野藥品工業股份有限公司 雙特異性蛋白質
KR20220070201A (ko) * 2019-09-30 2022-05-30 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항-pd-1 항체 및 이의 용도
CN111018989B (zh) * 2019-12-16 2021-03-23 郑州大学 一种抗pd-l1单克隆抗体以及在制备抗癌药物方面的应用
CN113336847B (zh) * 2021-02-03 2022-08-23 上海莱馥医疗科技有限公司 一种抗pd-1抗体
CN113150154B (zh) * 2021-04-15 2022-05-10 博奥信生物技术（南京）有限公司 抗人pdl1单克隆抗体及其用途
CN113234160B (zh) * 2021-05-26 2022-05-27 广州爱思迈生物医药科技有限公司 一种抗pd-1抗体及其应用
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
CN114159557A (zh) * 2021-11-09 2022-03-11 北京东方百泰生物科技股份有限公司 一种治疗肿瘤疾病的联合用药组合物及应用
CN117209604B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN114539406B (zh) * 2021-12-31 2023-04-14 浙江大学 一种全人源抗PD-1的单克隆抗体No.8-3及其应用
CN114539407B (zh) * 2021-12-31 2023-04-18 浙江大学 一种全人源抗PD-1的单克隆抗体No.1-10及其应用
CN115925947B (zh) * 2022-09-27 2023-08-22 上海百英生物科技股份有限公司 一种亲和力成熟方法及抗人pd-l1单域抗体的亲和力成熟
CN117304327B (zh) * 2022-11-18 2024-04-05 上海百英生物科技股份有限公司 一种抗山羊IgG的兔单克隆抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109485727A (zh) * 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
DK2170959T3 (da) * 2007-06-18 2014-01-13 Merck Sharp & Dohme Antistoffer mod human programmeret dødsreceptor pd-1
US8168757B2 (en) * 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN104250302B (zh) * 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
ES2792183T3 (es) * 2013-09-13 2020-11-10 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
CN103525868B (zh) 2013-10-17 2015-01-21 百泰生物药业有限公司 哺乳动物细胞高效表达载体的构建及应用
CN104479020B (zh) * 2014-12-26 2019-08-02 上海复宏汉霖生物技术股份有限公司 一种抗pd-1人源抗体
CN105061597B (zh) * 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法

Also Published As

Publication number Publication date
WO2016197497A1 (zh) 2016-12-15
AU2015398193B2 (en) 2018-10-25
KR20170020933A (ko) 2017-02-24
CA2972833A1 (en) 2016-12-15
CA2972833C (en) 2019-08-27
TW201643193A (zh) 2016-12-16
AU2015398193A1 (en) 2017-03-16
AR105619A1 (es) 2017-10-25
CN105061597B (zh) 2016-04-27
NZ728874A (en) 2019-08-30
US20170240644A1 (en) 2017-08-24
JP2017534247A (ja) 2017-11-24
SG11201705252UA (en) 2017-07-28
EP3176182A1 (en) 2017-06-07
BR112017010744A2 (pt) 2018-02-27
KR101876689B1 (ko) 2018-08-02
EP3176182A4 (en) 2017-11-29
CN105061597A (zh) 2015-11-18
HK1215870A1 (zh) 2016-09-23
EA201792584A1 (ru) 2018-07-31
TWI659969B (zh) 2019-05-21
EP3770177A1 (en) 2021-01-27
JP6588534B2 (ja) 2019-10-09
EA036779B1 (ru) 2020-12-21

Similar Documents

Publication Publication Date Title
MX2017008662A (es) Anticuerpos monoclonales anti-pd-1 y metodo para obtener los mismos.
PH12018550179A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
MX2020010382A (es) Anticuerpos biespecificos para pd1 y tim3.
SG10201808519VA (en) Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
PH12019502785A1 (en) Anti trbc1 antigen binding domains
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
MX2017005814A (es) Inmunoglobulinas hetero-dimericas de redireccionamiento de celulas t cd3/cd38 y sus metodos de produccion.
MY194994A (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
PH12019501089A1 (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
PH12016501212B1 (en) Human anti-il-33 neutralizing monoclonal antibody
MY190771A (en) Anti-pd-l1 antibodies and uses thereof
PH12017501732A1 (en) Therapeutic antibodies and their uses
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
WO2015173756A3 (en) Bispecific antibodies with engineered ch1-cl interfaces
NZ766660A (en) Anti-pd-l1 antibodies
WO2016205427A3 (en) Binding proteins against vegf, pdgf, and/or their receptors
JOP20190246A1 (ar) جسم مضاد أحادي النسيلة لـ pd-l1
MX2021014973A (es) Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso.
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
NZ710422A (en) Protein combination-based fv library, and preparation method therefor
IL280745A (en) Anti-FC epsilon-R1 alpha (FCER1A) antibodies, bispecific antigen-binding molecules that bind FCER1A and CD3, and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration